texas Children's Hospital and Baylor College of Medicine are set to launch Corbevax, a protein sub-unit Covid-19 vaccine in India, with plans to roll out in other underserved countries later.

The move comes after the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) for the vaccine, dubbed ‘The World’s COVID-19 Vaccine’.

Corbevax technology was engineered and created at the Texas Children’s Hospital Center for Vaccine Development (CVD).

The vaccine antigen’s initial construct and production process was also developed at CVD.

A traditional recombinant protein-based technology is used in the vaccine which enables the production at large scales making it widely accessible to the worldwide population.

After completion of two Phase III clinical studies conducted on more than 3000 participants, Corbevax was found to be safe, well tolerated, and immunogenic.

When assessed for neutralising antibody (nAb) geometric mean titers (GMT) against the Ancestral-Wuhan strain and Delta variant, the vaccine showed superior immune response compared to Covishield vaccine.

Corbevax also showed high persistence of immune response in the Phase II studies.